
Validation of Erythrocyte Mechanical Fragility as a Biometric for Performance Assessment of Circulatory Support DevicesAward last edited on: 2/5/2021
Sponsored Program
SBIRAwarding Agency
NIH : FDATotal Award Amount
$168,087Award Phase
1Solicitation Topic Code
-----Principal Investigator
Patrick HinesCompany Information
Functional Fluidics LLC
440 Burroughs Street
Detroit, MI 48202
Detroit, MI 48202
(313) 482-9435 |
info@functionalfluidics.com |
functionalfluidics.com |
Location: Single
Congr. District: 13
County: Wayne
Congr. District: 13
County: Wayne
Phase I
Contract Number: 1R43FD006939-01Start Date: 9/1/2020 Completed: 8/31/2021
Phase I year
2020Phase I Amount
$168,087Public Health Relevance Statement:
Mechanical circulatory support (MCS) devices provide cardiac and systemic support and reduce morbidity and mortality among high-risk patients, however their use is subject to a range of complications. However, a lack of standardized testing and quantification of blood damage causes uncertainties in evaluation of such devices, as there are no accepted tests to assess sub-lethal blood trauma. Development of a Mechanical Fragility Testing System (MFTS) that would enable better evaluation of MCS-induced damage in device development and approval process, and in the future potentially serve to monitor MCS clinical performance by assessing device performance, patient-specific hemolysis, and hemodynamic risks.
Project Terms:
No Project Terms available.
Phase II
Contract Number: ----------Start Date: 00/00/00 Completed: 00/00/00